PHD2/HDACs-IN-1
PHD2/HDACs-IN-1 is a potent PHD2/HDACs hybrid inhibitor (IC50s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively) . PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI) [1].
Product Specifications
CAS Number
2339867-53-5
UNSPSC
12352005
Target
HDAC; HIF/HIF Prolyl-Hydroxylase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/phd2-hdacs-in-1.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CN=C(N2CCC(NC(C3=CN=C(N4N=CC=C4)NC3=O)=O)CC2)N=C1)NO
Molecular Formula
C18H19N9O4
Molecular Weight
425.40
References & Citations
[1]Wei H, et al. Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. Eur J Med Chem. 2022;230:114115.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC2; HDAC6
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Bcl-2 (Apoptosis & Follicular Lymphoma Marker) (BCL2/1878R), CF647 conjugate, 0.1mg/mL
CD23 (Fc Epsilon RII) (FCER2/3592), CF568 conjugate, 0.1mg/mL
